Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Efficacy of potential therapy for autoimmune disorder of muscle weakness

08.10.2014

Nearly 60,000 Americans suffer from myasthenia gravis (MG), a non-inherited autoimmune form of muscle weakness. The disease has no cure, and the primary treatments are nonspecific immunosuppressants and inhibitors of the enzyme cholinesterase.

Now, a pair of researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a fast-acting "vaccine" that can reverse the course of the disease in rats, and, they hope, in humans. Jon Lindstrom, PhD, a Trustee Professor in the department of Neuroscience led the study, published in the most recent issue of the Journal of Immunology, with senior research investigator Jie Luo, PhD.

Acetylcholine Receptor

Myasthenia gravis is caused by an autoimmune response to the acetylcholine receptor (pictured here), a muscle protein that translates nervous system signals into muscle contractions.

Credit: Drawing courtesy of Jon Lindstrom, PhD, Perelman School of Medicine, University of Pennsylvania

MG is caused by an autoimmune response to the acetylcholine receptor (AChR), a muscle protein that translates nervous system signals into muscle contractions. Autoantibodies target the part of these receptors found on the outer cell surface of muscle, leading to weakness.

Researchers can induce MG in rats by injecting the AChR protein, which produces an animal disease model called experimental autoimmune myasthenia gravis (EAMG). In this study, Lindstrom and Luo found that injecting rats with the part of the AChR found on the inside of the cell protects those animals from EAMG and reverses the course of the disease if administered after the EAMG has already been induced.

"We have an antigen-specific immunosuppressive therapy that works on the animal model and should work on human MG," says Lindstrom, adding that such therapies are "rarer than hens' teeth."

A vaccine dose of 1 mg per week for six weeks, the team found, was sufficient to block development of chronic EAMG in rats. But significantly, the vaccine also worked after induction of chronic EAMG, and could block re-induction of disease months later, as well. The vaccine appears to work by preventing synthesis of pathological antibodies to the extracellular surface of the AChR protein.

Although called a "vaccine," Lindstrom's therapeutic is not like a vaccine for influenza or measles. In those cases, the idea is to raise immunity to disease antigens that can then attack the pathogen should it infect the body in the future. In the case of MG, the vaccine targets immune cells that recognize and target a self protein – the acetylcholine receptor, which helps transmit neural signals from cell to cell – and marks them for death.

"We are trying to modulate a deviant immune response," Lindstrom explains.

The trick here is that the vaccine is made not from the portion of the AChR protein that the immune system normally would see – that part that is exposed on the outer surface of cells. Instead, it is built using the protein's cytoplasmic, or inner, cell regions. This formulation induces a robust, antigen-specific suppression of the immune response without also inducing MG itself. This may involve inhibition of cells involved in making pathological antibodies and regulating that response, but the exact mechanisms have not yet been determined.

Lindstrom's lab first described the vaccine itself in a 2010 publication in the Annals of Neurology. But this earlier work didn't try to block or treat chronic disease, and injected the vaccine without the use of a chemical cocktail that amplifies the resulting immune response, called an adjuvant. The present study suggests that pairing the vaccine with an adjuvant is safe – that is, it doesn't cause MG – and effective.

Now, says Lindstrom, the goal is to test this approach in animals with EAMG and MG using other human adjuvants and then move to human clinical trials.

###

The research was funded by the Muscular Dystrophy Association.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.

Karen Kreeger | Eurek Alert!
Further information:
http://www.uphs.upenn.edu/news/

More articles from Health and Medicine:

nachricht Finnish research group discovers a new immune system regulator
23.02.2018 | University of Turku

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>